This is a preview of subscription content, log in via an institution to check access.
References
Isidro, J., Borges, V., Pinto, M., Sobral, D., Santos, J.D., Nunes, A., Mixão, V., Ferreira, R., Santos, D., Duarte, S., et al. (2022). Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med 28, 1569–1572.
Lum, F.M., Torres-Ruesta, A., Tay, M.Z., Lin, R.T.P., Lye, D.C., Rénia, L., and Ng, L.F.P. (2022). Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol 22, 597–613.
Mirdita, M., Schütze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., and Steinegger, M. (2022). Colab-Fold: making protein folding accessible to all. Nat Methods 19, 679–682.
Nolasco, S., Vitale, F., Geremia, A., Tramuto, F., Maida, C.M., Sciuto, A., Coco, C., Manuele, R., Frasca, E., Frasca, M., et al. (2023). First case of monkeypox virus, SARS-CoV-2 and HIV co-infection. J Infect 86, e21–e23.
Nuzzo, J.B., Borio, L.L., and Gostin, L.O. (2022). The WHO declaration of monkeypox as a global public health emergency. JAMA 328, 615–617.
Sang, Y., Zhang, Z., Liu, F., Lu, H., Yu, C., Sun, H., Long, J., Cao, Y., Mai, J., Miao, Y., et al. (2023). Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Sig Transduct Target Ther 8, 172.
Wolff Sagy, Y., Zucker, R., Hammerman, A., Markovits, H., Arieh, N.G., Abu Ahmad, W., Battat, E., Ramot, N., Carmeli, G., Mark-Amir, A., et al. (2023). Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med 29, 748–752.
Zaeck, L.M., Lamers, M.M., Verstrepen, B.E., Bestebroer, T.M., van Royen, M.E., Götz, H., Shamier, M.C., van Leeuwen, L.P.M., Schmitz, K.S., Alblas, K., et al. (2023). Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med 29, 270–278.
Zeng, J., Li, Y., Jiang, L., Luo, L., Wang, Y., Wang, H., Han, X., Zhao, J., Gu, G., Fang, M., et al. (2023). Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. Emerg Microbes Infect 12, 2204151.
Zhang, N., Cheng, X., Zhu, Y., Mo, O., Yu, H., Zhu, L., Zhang, J., Kuang, L., Gao, Y., Cao, R., et al. (2023a). Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity. Sci China Life Sci 66, 2329–2341.
Zhang, R.R., Wang, Z.J., Zhu, Y.L., Tang, W., Zhou, C., Zhao, S.Q., Wu, M., Ming, T., Deng, Y.Q., Chen, Q., et al. (2023b). Rational development of multicomponent mRNA vaccine candidates against mpox. Emerg Microbes Infect 12, 2192815.
Acknowledgement
This work was supported in part by Beijing Nova Program of Science and Technology (20220484127) and National Natural Science Foundation of China (82171818).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The author(s) declare that they have no conflict of interest. A provisional patent application has been submitted by Beijing Institute of Biotechnology (202211699094.7).
Supporting Information for
Rights and permissions
About this article
Cite this article
Yang, Y., Zhao, X., Li, Y. et al. Rational design of a single-component mRNA vaccine against orthopoxvirus and SARS-CoV-2. Sci. China Life Sci. 67, 1311–1313 (2024). https://doi.org/10.1007/s11427-023-2515-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-023-2515-0